Blue Rock Therapeutics

Boston, United States Founded: 2016 • Age: 10 yrs Acquired By Leaps by Bayer
Stem cell therapies are developed for cardiovascular and neurological diseases.
Request Access

About Blue Rock Therapeutics

Blue Rock Therapeutics is a company based in Boston (United States) founded in 2016 was acquired by Leaps by Bayer in August 2019.. Blue Rock Therapeutics has raised $225 million across 1 funding round from investors including Versant Ventures and Leaps by Bayer. The company has 138 employees as of December 31, 2022. Blue Rock Therapeutics offers products and services including bemdaneprocel and OpCT-001. Blue Rock Therapeutics operates in a competitive market with competitors including Merck, Roivant Sciences, Gilead, Lilly and Vertex Pharmaceuticals, among others.

  • Headquarter Boston, United States
  • Employees 138 as on 31 Dec, 2022
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Bluerock Therapeutics Lp
Operational Areas
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Services & Infrastructure
Healthcare → Healthcare Products & Supplies
Healthcare → Pharmaceuticals & Therapeutics
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $225 M (USD)

    in 1 rounds

  • Latest Funding Round
    $225 M (USD), Series A

    Dec 12, 2016

  • Investors
  • Employee Count
    138

    as on Dec 31, 2022

  • Acquired by
    Leaps by Bayer

    (Aug 08, 2019)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Blue Rock Therapeutics

Blue Rock Therapeutics offers a comprehensive portfolio of products and services, including bemdaneprocel and OpCT-001. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Investigational therapy for treating Parkinson's disease in clinical trials.

Therapy for primary photoreceptor diseases through iPSC-derived cells.

People of Blue Rock Therapeutics
Headcount 50-200
Employee Profiles 202
Board Members and Advisors 8
Employee Profiles
People
Shannon Mann
Scientist
People
Angus Lam
Senior Research Associate
People
Ryan Smith
Senior Scientist, Dopamine Cell Biology
People
Robert Gooding
IT Manager, Infrastructure

Unlock access to complete

Board Members and Advisors
people
Bruce Blazar
Scientific Advisor
people
Michael Laflamme
Scientific Advisor
people
Gordon Keller
Scientific Advisor
people
Viviane Tabar
Scientific Advisor

Unlock access to complete

Funding Insights of Blue Rock Therapeutics

Blue Rock Therapeutics has successfully raised a total of $225M through 1 strategic funding round. The most recent funding activity was a Series A round of $225 million completed in December 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 1
  • Last Round Series A — $225.0M
  • First Round

    (12 Dec 2016)

  • Investors Count 2
Date Amount Transaction Name Valuation Lead Investors Investors
Dec, 2016 Amount Series A - Blue Rock Therapeutics Valuation Versant Ventures , Leaps by Bayer
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Blue Rock Therapeutics

Blue Rock Therapeutics has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Versant Ventures and Leaps by Bayer. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Investor Description Founded Year Domain Location
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999.
Founded Year Domain Location
Venture capital firm investing in life sciences sector
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Blue Rock Therapeutics

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Blue Rock Therapeutics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Blue Rock Therapeutics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Blue Rock Therapeutics

Blue Rock Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, Roivant Sciences, Gilead, Lilly and Vertex Pharmaceuticals, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Pharmaceutical products are manufactured and marketed worldwide.
domain founded_year HQ Location
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
domain founded_year HQ Location
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others
domain founded_year HQ Location
Traditional pharmaceutical medicines are developed for multiple health fields.
domain founded_year HQ Location
Developer of drugs for the treatment of multiple disorders
domain founded_year HQ Location
Biopharmaceutical research and drug development are conducted globally by AbbVie.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Blue Rock Therapeutics

Frequently Asked Questions about Blue Rock Therapeutics

When was Blue Rock Therapeutics founded?

Blue Rock Therapeutics was founded in 2016.

Where is Blue Rock Therapeutics located?

Blue Rock Therapeutics is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.

Is Blue Rock Therapeutics a funded company?

Blue Rock Therapeutics is a funded company, having raised a total of $225M across 1 funding round to date. The company's 1st funding round was a Series A of $225M, raised on Dec 12, 2016.

How many employees does Blue Rock Therapeutics have?

As of Dec 31, 2022, the latest employee count at Blue Rock Therapeutics is 138.

What does Blue Rock Therapeutics do?

Blue Rock Therapeutics was founded in 2016 and is based in Boston, United States. Operations center on the biotechnology sector, where stem cell therapeutics are developed to address cardiovascular and neurological conditions. The lead program targets heart muscle regeneration for patients recovering from heart attacks or managing chronic heart failure. Additional efforts extend to broader neurological applications through stem cell-based treatments.

Who are the top competitors of Blue Rock Therapeutics?

Blue Rock Therapeutics's top competitors include Merck, Roivant Sciences and AbbVie.

What products or services does Blue Rock Therapeutics offer?

Blue Rock Therapeutics offers bemdaneprocel and OpCT-001.

Who are Blue Rock Therapeutics's investors?

Blue Rock Therapeutics has 2 investors. Key investors include Versant Ventures, and Leaps by Bayer.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available